Shares of Repligen Co. (NASDAQ:RGEN – Get Free Report) have been assigned an average rating of “Moderate Buy” from the nine ratings firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average 1-year […]
Alyeska Investment Group L.P. acquired a new stake in shares of Repligen Co. (NASDAQ:RGEN – Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 398,003 shares of the biotechnology company’s stock, valued at approximately $67,008,000. Alyeska Investment Group L.P. owned about […]
Stephens Investment Management Group LLC reduced its holdings in Repligen Co. (NASDAQ:RGEN – Free Report) by 3.2% during the first quarter, Holdings Channel.com reports. The institutional investor owned 528,464 shares of the biotechnology company’s stock after selling 17,490 shares during the quarter. Repligen accounts for about 1.5% of Stephens Investment Management Group LLC’s investment portfolio, […]
Stephens Investment Management Group LLC decreased its position in shares of Repligen Co. (NASDAQ:RGEN – Free Report) by 3.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 528,464 shares of the biotechnology company’s stock after selling 17,490 shares […]
Cerity Partners LLC increased its position in shares of Repligen Co. (NASDAQ:RGEN – Free Report) by 333.5% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 7,929 shares of the biotechnology company’s stock after buying an additional 6,100 shares during the period. Cerity Partners LLC’s holdings […]